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Background: Recent studies suggest that the incidence of idiopathic pulmonary fibrosis (IPF) is rising. Accurate
epidemiological data on IPF, however, are sparse and the results of previous studies are contradictory. This study
was undertaken to gain insight into the various methods used in the epidemiological research of IPF, and to get
accurate and comparable data on these different methodologies.
Methods: A systematic database search was performed in order to identify all epidemiological studies on IPF after
the previous guidelines for diagnosis and treatment were published in 2000. Medline (via Pubmed), Science Sitation
Index (via Web of Science) and Embase databases were searched for original epidemiological articles published in
English in international peer-reviewed journals starting from 2001. After pre-screening and a full-text review, 13
articles were accepted for data abstraction.
Results: Three different methodologies of epidemiological studies were most commonly used, namely: 1) national
registry databases, 2) questionnaire-based studies, and 3) analysis of the health care system’s own registry
databases. The overall prevalence and incidence of IPF varied in these studies between 0.5–27.9/100,000 and
0.22–8.8/100,000, respectively. According to four studies the mortality and incidence of IPF are rising.
Conclusions: We conclude that there are numerous ways to execute epidemiological research in the field of IPF.
This review offers the possibility to compare the different methodologies that have been used, and this information
could form a basis for future studies investigating the prevalence and incidence of IPF.
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Diagnostics and treatment of idiopathic pulmonary fi-
brosis (IPF) is currently undergoing changes. In the most
recent guidelines [1], the diagnostic criteria of IPF are
defined more accurately than they have been previously.
Simultaneously, IPF treatment is undergoing the biggest
shift in its history; the first drug intended for the preven-
tion of IPF progression, pirfenidone, is entering clinical
use in Europe, Canada and Asia [2,3]. In addition, an
interim publication of the PANTHER trial revealed that
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reproduction in any medium, provided the orprednisolone, azathioprine and N-acetylcysteine may be
harmful to IPF patients, since compared to those who
received placebo, individuals receiving triple-drug ther-
apy had increased mortality [4].
Epidemiological data of IPF are sparse, and moreover,
changes in classification of idiopathic interstitial pneu-
monias (IIP) and diagnostics make the comparison of
the data from various decades difficult. Until the 1990s,
idiopathic pulmonary fibrosis covered a heterogeneous
group of different interstitial diseases. The ATS/ERS con-
sensus statement of diagnosis and treatment in 2000 [5]
and classification of IIPs in 2002 [6] defined IPF more ac-
curately than it had been previously. In the new guideline
radiological and histological criteria of UIP (usual intersti-
tial pneumonia) are defined more precisely than before
[1]: If high-resolution computed tomography (HRCT)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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without histological analysis, whereas if HRCT features
show either possible UIP or no UIP features, a surgical
lung biopsy should be taken. Major and minor criteria are
no longer in use.
National IPF registries are being set up [7,8], and will
most likely yield important data on IPF epidemiology
after the diagnostic criteria revision. Therefore it is cru-
cial to summarize the existing data from 2001–2011 for
comparative purposes, and for a critical evaluation of
epidemiological methods that can be put into practice in
future studies.
Methods
Our aim was to review the literature of IPF epidemiology
that has been published after the previous international
statement on IPF in 2000. Therefore, we performed a
systematic literature search in September 2012 with the
help of an information specialist at the University of
Turku/Medical library. Relevant literature was identified
through the databases Medline (via Pubmed) and Science
Citation Index (via Web of Science) starting from 01/01/
2001 onwards. Only articles published in English were in-
cluded in the study. The search was limited to human
adults, using the terms idiopathic pulmonary fibrosis,
interstitial lung diseases and epidemiology, combined with
geographical areas (Americas, Australia, Europe, Asia and
cities). The initial search resulted in 214 articles. Two
authors (JK, MM) independently pre-screened titles and
abstracts, and data extraction resulted in 28 articles. All
articles containing demographic data, incidence, preva-
lence or mortality rates of IPF or interstitial lung diseases
(ILD), also including IPF patients, were accepted.
The 28 eligible articles were then full-text reviewed by
four authors (JK, RK, E-RS and MM). By consensus, only
international peer-reviewed original articles were included,
leading to the exclusion of seven review articles and one
comparative report of ILD registries in three European
countries [9]. Two studies that identified racial differences
in IPF epidemiology were excluded [10,11], as they did not
represent overall incidence or prevalence calculations.
The other disqualified original articles (n = 6) contained
insufficient demographical data or insufficient cohort: art-
icle on prognostic factors and causes of death in Korean
patients with IPF [12], Japanese case–control study of
relationship between medical history and the risk of IPF
[13], retrospective analysis of lower occurrence of IPF in
Maori and Pacific Islanders [14], seasonal variation of
mortality of pulmonary fibrosis [15], first report of the
RIPID [16] and an Indian study of etiology of biopsy
proven ILD [17].
An additional search was conducted in June 2013 to
complement the systematic analysis. Embase was searched
using the same queries as initially. 942 articles were foundand titles were pre-screened by one author (JK). One add-
itional article – published after September 2012 – was
added to this systematic review. A summary of the selec-
tion process of articles is presented in Figure 1.
After the final evaluation, 13 articles were selected for
data abstraction (Table 1.). Of the patient cohorts in
these 13 articles, six were defined according to the ATS/
ERS 2000 guidelines (Table 2).
Results
From the 13 articles chosen for this review, we identified
three commonly-used methods for the evaluation of IPF
epidemiology in a population, and used this knowledge to
categorize epidemiological studies in order to simplify the
comparison of heterogeneous population data (Table 1).
First, we identified national registries of ILDs (here, two
such studies were included [18,19]), where data collection
was based on the activity of physicians. Second, two stud-
ies [20,21] were based on questionnaires for pulmonary
physicians. A third, and by far the most common type of
approach to IPF epidemiology, was the use of pre-existing
databases, such as hospital databases and death registers,
to calculate the overall prevalence and mortality of IPF
[22-30]. Five studies included all ILDs (where IPF was
usually the most common form) whereas in seven studies
the focus was solely on IPF. In one report, the term pul-
monary fibrosis, PF was used.
National ILD registries
In Flanders—the northern part of Belgium—20 centers
of respiratory medicine took part in the registration of
ILD patients between the years 1992–1996 [18]. The
twenty largest centers were relatively evenly distributed
over the five provinces of Flanders. It was trusted that the
registry consisted of a reliable percentage of the distribu-
tion of the ILD; it should be noted, however, that several
centers did not participate in this collaborative study.
Guidelines for diagnostic evaluation, therapy and follow-
up recommendations of ILD were sent to pneumologists.
Liebow’s classification from 1975 [31] was used for IPF
definition. A total of 362 ILD cases were registered.
IPF was the second most common ILD (20%) after
sarcoidosis. Of the 72 patients with IPF, 21 (29%) had
biopsy-proven UIP, 10 patients had bronchiolitis obliterans
organizing pneumonia (BOOP), nine had desquamative
interstitial pneumonia (DIP), three had lymphocytic inter-
stitial pneumonia (LIP) and in 29 cases (40%) the histology
was not specified. The cases with biopsy proven IPF/UIP
were identified according to the ATS/ERS 2000 guidelines
[5]. Again male predominance was found, at 58.3% (with
male/female ratio 1.4). The average age at diagnosis was
57 years. In Flanders, the registry data suggests an inci-
dence of 0.22/100,000 and prevalence of 1.3/100,000 of
IPF, which is significantly less than in comparable studies
Pre-screening (titles, 
abstracts)
n=214
Full-text review of n=28 
articles
Inclusion of: original 
articles, international peer-
reviewed in which 
prevalence, incidence, 
mortality and/or 
demographical numbers are 
presented
n=12
Exclusion of 186 articles
-not epidemiological
-not demographical
-not ILD/IPF
Additional search to 
Embase in June 2013
Exlusion of: 
7 review articles
8 original articles
1 comparative study
Initial search in September 
2012
Pubmed and Web of 
Science
Screening (titles)
n=942
Exclusion of 941 articles
-duplicates
-not epidemiological
-not ILD/IPF
One article (published after 
initial search) included to 
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Accepted to the systematic 
review
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Figure 1 Graphic presentation on article selection to this study. Embase database became available to the authors after the initial search in
2012, therefore an additional study was performed in 2013.
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that the low prevalence of IPF was primarily due to a
selection bias by the type of registry or applied diagnos-
tic procedures.
The Italian register for diffuse infiltrative lung disor-
ders (RIPID) was established in 1998 [19]. Registration
was voluntary, and implemented by 138 physicians in 79centers located in all 20 regions of Italy. The greatest num-
bers of these cases were from northern Italy (74.3%), and a
minor fraction from central Italy (11.3%) and southern
Italy (14.4%). The accuracy of the data in regard to the
international diagnostic criteria (ATS/ERS 2000) could not
be verified as it relied on the quality of the input received
from the different physicians in different institutions. Up to
Table 1 The articles included in this systematic review, categorized by the methodology used
Type of study Author Year & journal Study period Cases (N) Prev., Inc., mortality
National registry data Thomeer et al. Acta Clin Belg 2001 1992-1996 72 Prevalence 1.25
Incidence 0.22
Tinelli et al. Sarcoidosis Vasc Diffuse Lung
Dis 2005
1998-2005 864 -
Questionnaires Xaubert et al. Sarcoidosis Vasc Diffuse Lung
Dis 2004
10/2000-09/2001 197 (Inc) Incidence 2.94
Karakatsani et al. Respir Med 2009 2004 189 (Prev) Prevalence 3.38
52(Inc) Incidence 0.93
Analysis of pre-existing
database
Hodgson et al. Thorax 2002 1997-1998 1445 Prevalence 16-18
von Plessen et al. Respir Med 2003 1984-1998 158 Prevalence 19.71-23.42 (CFA)
Incidence 4.3 (CFA)
131.12.1991, 231.12.1998
Gribbin et al. Thorax 2006 1991-2003 920 Incidence 4.6
Raghu et al. Am J Respir Crit Care Med
2006
01/1996-12/2000 1943 (broad) Prevalence, 42.7 (broad)
387 (narrow) Prevalence, 14.0 (narrow)
Incidence, 16.3 (broad)
Incidence, 6.8 (narrow)
Olson et al. Am J Respir Crit Care Med
2007
1992-2003 175,088 Mortality 50.8 (PF)
Ohno et al. Respirology 2008 2005 1322 Prevalence 3.44 (IIP)
Fernández Pérez et al. Chest 2010 1997-2005 47 Prevalence 27.9 (narrow)
Prevalence 63 (broad)
Incidence 8.8 (narrow)
Incidence 17.4 (broad)
Navaratnam et al. Thorax 2011 mort.1968-2008 56,675 Mortality 2.54
inc.2000-2008 2,074 Incidence 7.44
Lai et al. Respir Med 2012 1997-2007 418 (Prev) Prevalence 0.71-6.42 (broad)
Prevalence 0.51-4.92 (narrow)
Incidence 0.61-1.42 (broad)
Incidence 0.51-1.22 (narrow)
1in 1998, 2in 2007
Prevalence (Prev) Incidence (Inc) and mortality/100,000.
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cluded. IPF was the second most common ILD after sar-
coidosis consisting of 27.4% of patients (n = 864). Until
1999–2000 the number of IPF cases diagnosed was rising
in Italy, but during 2000–2005 this remained constant.
There was a slight male predominance in this data (62.6%),
which is a usual finding in all studies on IPF [32]. The
mean age of onset was 68 years. Epidemiological parame-
ters, such as incidence and prevalence, were not accurately
calculated since the size of the population (of the partici-
pating centers) was not available.
Both of these national registry studies rely considerably
on the activity of physicians in reporting patient numbers
and data, and studies performed in this way should alwaysbe interpreted knowing of this bias, that results in under-
estimation of patient numbers. Registry cohorts like these,
are, however important in the determination of patient
clinical course and the possible differences in the manage-
ment of patients in different centers.
Questionnaire-based surveys of ILD in Greece and Spain
Two methodologically similar articles were found from
Greece and Spain, where a standardized questionnaire
was sent to respiratory medicine centers in order to ob-
tain information on patients’ clinical data, procedures
used to establish the diagnosis and the exact diagnosis.
In Spain, a registry of incident cases of ILD was set up
from October 2000 to September 2001 [20]. A total of
Table 2 Characteristics of IPF patients’ demographics according to the studies included
Study Mean/median
age at Dg
Male/
Female
Total no of cases/ ATS/ERS 2000/2002 Before ATS/ERS
2000/2002
Re-evaluation
% IPF of ILD Dg criteria used
Thomeer et al. 2001 57 years 58/42% 362/20% X Liebow 1975
Tinelli et al. 2005 68 years 63/37% 3152/27% X
Xaubert et al. 2004 511/38.6% X
Karakatsani et al. 2009 967/20% X
Hodgson et al. 2002 X X
von Plessen et al. 2003 69.2 45/55 X Turner-Warwick X
Gribbin et al. 2006 71 years 62/38% X
Raghu et al. 2006 X
Olson et al. 2007 X
Ohno et al. 2008 65 years 1543/85.7% X
Fernández Pérez et al. 2010 74 years X X
Navaratnam et al. 2011 74 years 63/37% X
Lai et al. 2012 X
% IPF of ILD. All of the ILD studies included sarcoidosis patients.
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and participated. These 23 centers covered a population
of 6.7 × 10 6 inhabitants. A standardized questionnaire
was sent to the centers. An ATS/ERS consensus state-
ment from 2002 was applied for classifying ILDs. A total
of 511 cases of ILD were registered. Idiopathic pulmon-
ary fibrosis was the most frequent disease, covering 197
patients/38.6% of all ILD patients; thus, according to our
calculation, this results in an incidence of 2.94/100,000.
The diagnosis was established by a surgical lung biopsy
in 31.5%, and clinical criteria including HRCT scanning
in 68.5%.
In Greece, departments of Pneumonology were con-
tacted, and pneumonologists were asked to complete a
questionnaire for all ILD patients who were alive in 2004
(prevalent case), as well as for every new incident case
diagnosed during 2004 [21]. Centers covering about 60%
of the Greek adult population (5.6 million inhabitants)
replied and participated in the study. For the classifica-
tion of the IIPs the ATS/ERS consensus from 2002 was
used. Due to funding limitations, no reevaluation of the
cases could be done. A total of 967 cases of ILD were
reported during 2004. Idiopathic pulmonary fibrosis
accounted for about 20% of all ILDs. Open lung biopsy
was performed in 18.5%, and a VATS biopsy in 13.2%, of
IPF cases. The number of prevalent cases (IPF/UIP) was
189 (19.5%), and the number of incident cases was 52
(20.1%) The prevalence of IPF in 2004 in Greece was cal-
culated to be 3.38/100,000 and incidence 0.93/100,000.
Due to the low response rates and lack of monitoring of
the centers that have attended the study, data derived
from these two studies should be interpreted with caution.Analysis of health care system registries
In Finland, the prevalence of sporadic and familial IPF
was evaluated during the years 1997–1998 [22]. All
Finnish pulmonary clinics (N = 29) were contacted, and
hospital databases were screened for ICD-10 diagnosis
J84.1. In selected hospitals (N = 13) the diagnoses were
reevaluated by a specialist in pulmonary medicine using
the ATS/ERS 2000 recommendations. The screening of
hospital diagnosis registries showed to be sensitive but
highly non-specific, since 23-51% of all cases were ex-
cluded. All five Finnish university hospitals and eight
smaller district hospitals were chosen for the study, to
ensure that all geographical areas were covered. The
total number of patients with IPF was extrapolated using
the screened and re-evaluated patient data. The study
group identified 1,445 inpatients or outpatients with the
diagnosis of IPF or fibrotic alveolitis. In 90% of the pa-
tients, lung involvement was assessed by HRCT scanning
and 28% of IPF patients had histological verification. No
predominance of either sex was observed. The preva-
lence of IPF in Finland was estimated to be 16–18/
100,000. Because the majority of the IPF cases were not
histologically verified, it was discussed by the study
group that this could be a source of uncertainty in the
prevalence estimates. The strong point in this particular
study was the reliability of population data due to a
comprehensive up-to-date national population registry,
and a high-standard health care system that is available
to all citizens. The weaknesses of this study were, that it
was performed very soon after the diagnostic criteria
were changed, and the cohorts did not include the
whole population.
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diagnosed and hospitalised cryptogenic fibrosing alveolitis
(CFA) was studied during 1984–1998 [23]. Thus, the study
started long before HRCT was available in all hospitals and
before ATS/ERS 2000 obtained. The diagnostic clinical cri-
teria by Turner-Warwick [33] was used. The study popula-
tion (Bergen hospital district) covered total of 250,000
inhabitants. A computer-aided search of the hospital regis-
ters was carried out. Two physicians abstracted data and
the following cases were excluded: pulmonary fibrosis asso-
ciated with collagen vascular disease, intake of cytotoxic
and other potentially fibrogenic drugs, radiotherapy and
exposure to asbestos as well as silica, sarcoidosis and aller-
gic alveolitis. The search resulted 376 patients of which
158 were defined as incident CFA cases. Mean age at
diagnosis of incident cases was 69.2 years and 45% were
men. Norwegian women are among the heaviest smokers
in the world. Smoking - as a probable risk factor for CFA -
may explain the female predominance, especially because
women are at higher risk developing respiratory disease.
The average annual incidence hospitalised CFA was 4.3/
100 000 inhabitants. The prevalence was 23.4/100 000 and
19.7/100 000 by 31.12.1998 and 31.12.1991 respectively.
Median survival of incident cases was 4.1 years. It should
be kept in mind that due to the diagnostic criteria used the
whole spectrum of idiopathic pulmonary fibrotic disorders
was included including i.e. nonspecific interstitial pneumo-
nia (NSIP). This study represents a very small, but carefully
and reliably analysed patient cohort, but due to the rela-
tively small patient number from the same area and genetic
background, the epidemiological parameters should be
interpreted with caution. However, compared with the
similarly performed study of Hodgson et al. [22], the preva-
lence of IPF is at a comparable level.
In the United Kingdom, a computerized longitudinal
general practice database (The Health improvement Net-
work, THIN) was analyzed to estimate the incidence of
IPF and sarcoidosis between 1991–2003 [24]. The term
IPF was used to describe clinical diagnosis because only
a small majority of patients were diagnosed with an open
lung biopsy. IPF patients were identified with diagnostic
terms: “cryptogenic fibrosing alveolitis” and “idiopathic
fibrosing alveolitis”. Patients were included if they had at
least one recorded IPF diagnosis, their first IPF diagnosis
was recorded at least 12 months after the patient’s first
mark in the database and they were aged at least 40 years
when they received the first diagnosis. The IPF patient
cohort was analyzed with a matched general-population
control cohort. There were 920 patients with IPF (≥
40 years at diagnosis) and 3,593 matched controls were
identified. The mean age at diagnosis was 71 years, and
62% were male. The overall incidence rate for IPF was
4.6/100,000. The crude rates also increased progressively
over time and tended to be higher in the northern andwestern regions of the UK. After controlling for the effects
of sex, age and geographical region, the estimated annual
increase in the incidence of IPF was 11%. The 3- and 5-
year survival percentages for patients with IPF were 57%
and 43%, respectively and the equivalent percentages in
the comparison cohort were 88% and 81%. The authors
questioned the validity of the IPF diagnoses, and despite
the study design some of the incidental IPF cases could be
prevalent. The main strength of this study was the large
size of the patient cohorts, and the coverage of the cohort
to the whole population. Compared to other studies, how-
ever, the prevalence is lower, suggesting that not all IPF
patients were found using this particular method. Patient
data were not re-evaluated, which can be considered as a
major weakness in this study.
In the United States, the annual incidence and preva-
lence of IPF was estimated by utilizing a large health
care claims database from 01/1996–12/2000 [25]. IPF pa-
tients were recognized through both broad and narrow
definitions. The broad case definition criteria included
age, ≥ 18 years, one or more medical claim with a diagno-
sis code for IPF (ICD-9-CM 516.3, not specific for IPF),
no medical claims with a diagnostic code for any other
ILDs on or after the date of the last medical claim with a
diagnosis code for IPF. The narrow case definition in-
cluded the broad case definition and one or more medical
claims with procedure codes for a surgical lung biopsy, a
transbronchial lung biopsy, or a computed tomography of
the thorax, on or before the date of the last medical claim
with a diagnosis code for IPF. From 2.2 million men and
women, 1,943 patients met the broad case definition;
among which, 387 met the narrow case definition. Based
on the broad case definition, the prevalence of IPF was es-
timated to range from 4.0/100,000 (age, 18–43 years) to
227.2/100,000 (≥75 years). Incidence ranged from 1.2 to
76.8/100,000, respectively. Based on the narrow definition,
prevalence was estimated to range from 0.8/100,000
(age18–34 years) to 64.7/100,000 (≥75 years) and inci-
dence from 0.4 to 27.1/100,000 respectively. Extrapolating
these rates to the overall population of the United States,
prevalence was estimated to be 42.7/100,000 and inci-
dence 16.3/100,000 using the broad criteria. With the nar-
row criteria, prevalence was estimated to be 14.0/100,000
and incidence 6.8/100,000. Both prevalence and incidence
was generally higher among men than women. According
to the authors, the limitations of this study were that the
database included only health-plan members in selected
geographic regions of the United States, data were col-
lected for the most part before the ATS/ERS consensus
and statement of the classification in 2002. The study
population consisted solely of persons that had insurance,
and who thus may differ systematically from the rest of
the population in terms of their health status and/or
medical-care utilization and expenditures. When this
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view, the narrow criteria for IPF result in very similar
prevalence rates as the health care system studies ie. in
Finland and Norway [22,23]. Due to a different kind of
health care system organization (publicly versus privately
funded) these studies are not comparable.
In another study conducted in the United States, mortal-
ity to pulmonary fibrosis (PF) was studied from 1992–2003
[26]. The National Center for Health Statistics’ (NCHS) da-
tabases was screened to calculate mortality rates and exam-
ine the underlying cause of death. From 1992 to 1998
NCHS coded conditions related to death with ICD-9, and
began using ICD-10 from 1999. From 1992 to 2003, there
were 28,176,224 deaths in the United States. Of these
deaths, a total of 175,088 records contained a diagnostic
code for pulmonary fibrosis. Using the entire subset of
175,088 decedents, the age-adjusted mortality rate in-
creased to 29.4% in men and 38.1% in women during the
study period. When connective tissue disease, asbestosis
and radiation fibrosis were excluded from the original ana-
lysis, the age-adjusted mortality rate increased over the
study period to 28.4% in men and 41.3% in women. In the
third analysis, the most rigorous definition in PF was used,
and records that contained codes for both PF and any
other condition known to cause PF were excluded. Ana-
lysis now showed mortality rates increasing to 27.5% in
men and 40.8% in women. The authors speculated that
persistently rising mortality rates might reflect an increase
in clinical recognition of pulmonary fibrosis during the
study period. The average age- and sex-adjusted mortality
rate to PF was 50.8/100,000. Mortality rates varied greatly
by state: states with the lowest mortality were New Jersey,
New York, Nevada and the District of Columbia. The
highest mortality rates were found from New Mexico, Ver-
mont, North Carolina and South Carolina. The authors
speculated that this geographic variation might have devel-
oped due to real differences between races, or there might
be differences in the identification of the disease, or differ-
ences in the rate of the use of diagnostic tests. In addition,
environmental factors were proposed to have an effect on
the pathogenesis of the disease. The most common cause
of death in this patient group was PF itself. The obvious
limitations in this study are that it relies on accuracy of a
particular death registry and that the patients included are
not reevaluated according to the modern diagnostic
criteria. The important value of this study is, however
the increases in mortality, which should be assessed in
future studies.
Clinical records were also utilized in Japan to gain epi-
demiological data of IIP [27]. All IIP patients who deliv-
ered medical benefits during 2005 were included in the
study. As medical benefits are examined in each prefec-
ture, clinical records were collected and submitted to
the Disease Strategy Section, Health Bureau, Ministry ofHealth, Labor and Welfare and then stored in a database
in the Ministry. It is noteworthy that IIP conditions, for
which medical benefits were delivered, corresponded to
severe cases; milder cases of IIP were thus not included
to this study. In 2005, medical benefits were delivered to
4,396 patients with IIP. Of these patients, clinical per-
sonal records were available for 1,543 patients. A total of
1,322 patients (85.7%) had IPF of which 545 were newly
diagnosed patients and 777 updated patients. The diagno-
sis was confirmed by surgical lung biopsy in 12% of the
patients. The mean age at disease onset was 64.5 years.
There was no gender difference. The prevalence of IIP
was estimated to be 3.44/100,000. According to this, the
prevalence of IPF would then be 2.95, which is likely to be
an underestimation, as mild disease forms were not
recorded. Again, this study shows that cultural differences
in health care registries may result in very dissimilar re-
sults when epidemiological data were collected.
In Olmsted County, Minnesota, during a nine-year
period (01/1997–12/2005) residents were screened, and
those with possible IPF were identified [28]. These
cases were identified through the diagnostic index (e.g.
ICD-9-code) using the resources of the Rochester Epi-
demiology Project (REP), which links together medical
diagnosis and procedure information across all medical
providers in the county. Medical care is essentially self-
contained within Olmsted County. Using REP ensured
that 100% of the cases within a defined geographic re-
gion were approached. IPF cases were identified by two
methods: 1) evidence of UIP on surgical lung biopsy
specimens or definite UIP pattern on HRCT (narrow-
case finding criteria) and 2) evidence of UIP on surgical
lung biopsy specimens or a definite or possible UIP pat-
tern on HRCT (broad-case finding criteria). The first
method met all major and minor ATS/ERS 2000 criteria
in the absence of a surgical lung biopsy, and the second
method included all patients in the first method and a
subgroup that met ATS/ERS criteria but in whom the
HRCT features were characterized as possible for UIP.
For each patient identified, their complete medical rec-
ord was reviewed by a trained data abstractor and one
of the investigators. In addition, for each case identified
the HRCT images were reviewed by two thoracic radi-
ologists and ranked as definite or possibly UIP or being
unlikely UIP. All lung biopsy specimens were re-analyzed
by a pulmonary pathologist to confirm the diagnosis of
UIP. For 596 patients screened, 47 new cases of IPF were
identified which could be viewed as too small for reliabil-
ity. Of these 47 patients, 24 met the defined narrow cri-
teria. The mean age at diagnosis was 73.5 years, and 29%
of patients had histologically proven UIP. The age- and
sex-adjusted incidence was 8.8/100,000 (narrow criteria)
and 17.4/100,000 (broad criteria). The incidence rate was
higher in men than in women, and highest among those
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decreased during the study period. The prevalence of IPF
in Olmsted County (on December 31, 2005) was 27.9/
100,000 (narrow criteria) and 63/100,000 (broad criteria).
During the 9-year observation period, the median sur-
vival for narrow and broad criteria was 3.47 years and
4.37 years, respectively. Although this report presented
a very small cohort of patients, it was one of the studies
in which reevaluation was conducted in a very reliable
manner, and thus this study might represent the most
reliable estimates of IPF epidemiological parameters.
In the United Kingdom, death registers and general
practice databases were used to investigate mortality
(1968–2008) and incidence (2000–2008) of IPF [29].
The diagnostic classifications used in both datasets were
not made according to the ATS/ERS 2000 classification,
which may result in the overestimation of cases. There
were 56,675 deaths attributed to IPF clinical syndrome
(IPF-CS) in England and Wales from 1968 to 2008.
Three different ICD codes were used to code death from
IPF-CS, namely ICD-8 code 517, ICD-9 codes 516.3,
515 and ICD-10 code J84.1. The overall mortality rate
standardized to the 2008 UK population was 2.54/
100,000. Mortality rates increased significantly during
the study period —from 0.92/100,000 during 1968–
1972 to 5.10/100,000 during 2006–2008 being higher in
men and the older age groups. In the same study the
sub analysis of the ICD-9 codes showed similar trends.
The primary care database recorded by UK general practi-
tioners—The Health Improvement Network (THIN)—
was also screened for diagnoses of IPF-CS between 2000–
2008. Cases with a co-existing connective tissue disease,
and individuals who had co-existing diagnoses of extrinsic
allergic alveolitis, asbestosis, pneumoconiosis and sarcoid-
osis were excluded. The search resulted in a total number
of 2,074 incident cases which equates to an incidence of
7.44/100,000. The majority (63%) of new cases were men.
The mean age at diagnosis was 74.3 years. After adjusting
for age, sex and health authority, the estimated annual in-
crease in the incidence of IPF-CS was 5%. The overall me-
dian survival for this cohort was 3.03 years. The advantage
in the methodology used here is the combination data de-
rived from of two different and independent registries, but
the results are handicapped with the lack of reevaluation
of the diagnostic accuracy of these registries.
In Taiwan, a large population-based study was con-
ducted to collect epidemiological information of IPF
among Asians [30]. The data were collected from two
Taiwanese governmental organizations –the Taiwan Na-
tional Health Insurance (NHI) system and the national
mandatory death registry system – during 1997–2007.
The NHI covers and protects almost all Taiwanese, and
has detailed information on health services (almost all
outpatient visits and hospital administrations), proceduresand prescriptions, their payments and times of use. Pa-
tients’ diagnoses were coded using the ICD-9. For com-
parative purposes, the same definitions of IPF were used
as in the study of Raghu et al. [25]. The broad definition
consisted of the following three conditions: 1) there was at
least one NHI claim with IPF diagnosis (ICD-9-CM code
516.3) between January 1, 1997 and December 31, 2007,
2) for at least one NHI claim with the diagnostis of IPF,
there were no NHI claims for any other ILDs after the day
of IPF diagnosis, 3) The patient’s age was ≥ 18 at the time
of confirming IPF. The conditions for the narrow defini-
tions were: 1) all conditions for the broad definitions were
met, 2) for at least one NHI claim with IPF diagnosis,
there was at least one NHI procedure for surgical lung bi-
opsy, or computed tomography of the thorax before or on
the day IPF diagnosis.
The estimated prevalence, based on the broad case
definition, ranged from 0.7 in 1998 to 6.4 in 2007.
According to the narrow case definition the estimated
prevalence was 0.5 in 1998 and 4.9 in 2007. The annual
incidence was calculated to be 0.6 in 1998 to 1.4 in 2007
(broad definition,). The incidence ranged 0.5 in 1998 to
1.2 in 2007 (narrow case definition, Table 1). Both preva-
lence and incidence increased during the study period ir-
respective of the case definition. Both prevalence and
incidence were generally higher among aged people (over
75 years) and men. The median survival time after IPF
diagnosis was 0.9 years or 0.7 year for the broad and nar-
row definitions, respectively. The authors pointed out, that
incidence and prevalence were found to be relatively lower
in Taiwan than in western countries. This was suspected
to be due to differences in diagnostics or in ethnics. Sur-
vival of the IPF patients was much shorter than in the
United States [28]. It was speculated that this could be
due to a delay in diagnosis; most of the Taiwanese patients
were diagnosed at advanced disease stages. The major
advantage in this study is the use of a health care regis-
try that covers the whole population. Unfortunately, the
identified patients were not reevaluated, which affects
study reliability and prevents comparisons to other
similar studies.
Discussion
Our systematic search on IPF epidemiological parame-
ters resulted in 13 eligible original articles published
after 2001, of which six used the ATS/ERS 2000 diagnos-
tic criteria or classification recommendations of IIP from
2002. Our results indicate that there exist only a few re-
ports on IPF epidemiology according to the modern
diagnostic criteria, and that all studies had either major
methodological limitations or a small cohort of patients,
which makes the comparison of epidemiological parame-
ters in these studies very difficult or impossible. No ori-
ginal articles have been published so far on IPF prevalence
Table 3 The possible reasons for the high variability of
epidemiological parameters observed in the different
studies
Epidemiological parameter Reason for variability
Prevalence Definition of disease
Diagnostic guidelines
Healthcare system related
Methodological differences
Incidence Improved diagnostics
Improved health care system
Ageing population
Drug availability
Mortality Clinical recognition
Changes in diagnostic coding
M/F ratio Occupational exposures
Population smoking habits
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from IPF registries [8,34]. The use of uniform, inter-
national diagnostic guidelines is of utmost importance in
the field of IPF medicine, and will most likely enable the
collection of more accurate and comparable data in the
future. It is, however, surprising that quite a few articles
have been published after the publication of the first diag-
nostic criteria in 2000, yet they did not make use of these
criteria by means of the reevaluation of patient data. Data
reevaluation requires access to a large set of patient data,
including histological lung biopsies and original CT scans,
and often requires a complete search of all medical re-
cords, perhaps making it too laborious and costly. How-
ever, as our literature search showed, this has been done
in restricted patient cohorts [22,23,28], and could well be
standardized as a method for future studies. Uniform elec-
tronic patient journals and digital image archives may
offer some help in this setting, making the collection and
evaluation of epidemiological data easier for scientists in
the future. Thus it is important to collect data in such a
way that even if the diagnostic criteria change, the data
could still be used.
In addition to the identification of epidemiological pa-
rameters, our primary aim was to identify plausible and
reliable methods in studies related to IPF epidemiology,
as the field of IPF medicine is undergoing considerable
change due to specific drugs that are entering clinical
use, and many nationwide registry databases which are
currently being built. Various and very heterogeneous
methods are being used by IPF researchers, and so far
the data from these studies is not comparable between
countries due to this variation. We identified three cat-
egories or strategies for collecting IPF epidemiological
data: nationwide registries for IPF or ILD, such as the
Italian registry; questionnaires for health-care profes-
sionals; and systematic searches from existing databases.
From these methods, questionnaires seemed to produce
the lowest prevalence rates compared to national regis-
tries and/or searches from pre-existing databases. The
coverage of pre-existing databases might be high in cases
such as those shown in the study of Navaratnam [29],
but the downside of this kind of study rationale is the
high number of patients that have been misdiagnosed i.
e. having a high number of “false positive” cases.
The number of incidental and prevalent cases varied
greatly in the presented studies (prevalence from 0.5
[30] to 27,9/100,000 [28]). In some of the selected arti-
cles e.g. [18,21], it was speculated that this variation may
be due to real differences between countries. Our results
suggest that, primarily, the differences in epidemiological
parameters are more likely to be a result of the heteroge-
neous methods used than true geographical differences
in IPF epidemiology. The fact that studies which used
very similar methodologies resulted in similar results(for example the questionnaire studies, where the inci-
dence ranged from 0.93 to 2.94/100,000) supports this
view. However, even these studies are not comparable as
the questionnaires used, and the strategies for obtaining
answers, were different. The possible differences in re-
sults between epidemiological studies are summarized in
Table 3. One shared problem in all methods is the diffi-
culty of finding the right denominator to epidemiological
calculations. For example in the registry study of Thomeer
et al. [18] low prevalence and incidence rates may be due
to overly high denominator; not all but 20 centers partici-
pated to the study which doubtfully covers the whole
Flanders population. In addition, the lack of a specific
diagnostic coding for IPF, that would differentiate it from
other ILDs has not existed before the 2013 version of the
ICD-10 diagnostic system.
Changes in diagnostic criteria may also explain some
of the observed variation. Studies implemented before
the ATS/ERS 2000 guidelines [5] have shown the lowest
prevalence at 0.5 in Taiwan [30] and the highest in
Norway at 23.4 [23]. After the publication of more de-
finitive diagnostic criteria, prevalence has varied between
3.38 [21] to 27.9 [28]. Until the 1990s, the Liebow classi-
fication of idiopathic interstitial pneumonia (IIP) was
used, which did not include NSIP [35]. NSIP was de-
scribed in 1994 [36], and subsequently a new proposal of
the classification of IIPs, which also included NSIP, was
presented by Katzenstein and Myers in 1998 [37]. Until
this proposal, NSIP was probably diagnosed mostly as
IPF or, in some cases, also as desquamative interstitial
pneumonia (DIP). The international guidelines of IPF
and IIP in 2000 and 2002 recommended that NSIP
should be separated from IPF, which has been gradually
implemented into the clinical practice during the 2000s.
Thus, it is likely that most of the studies in the present
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addition to IPF, at least in the beginning of the study pe-
riods, because of the historical background and the change
in classifications. Currently a new classification of IIPs is
being updated which will include a new category, namely
unclassifiable IIP [38], which has been shown to comprise
about 10% of an ILD cohort [39]. It may be reasonable to
assume that in the above-mentioned epidemiological stud-
ies not only the patients with NSIP, but also those with
unclassifiable fibrosis, may have been included.
The international disease classifications have also
reflected the lack of a clear, systematic classification of
ILD:s: only in the latest version of ICD-10 from 2013,
there has been a separarate subclassification for IPF. It is
to be expected, that studies performed after this disease
classification has been taken into use, and in countries
where the population registries are most reliable, will
yield high-quality data on IPF epidemiology. There are
already preliminary reports on several national registry
studies, which hopefully will yield comparable data on
IPF epidemiology in different geographical and cultural
areas [7,40,41].
Conclusions
Overall, it can be concluded that the existing databases
present an overestimation of patient numbers, whereas
registries and questionnaire-type studies result in an
underestimation of patient numbers. The acquirement
of accurate epidemiological data is crucial in elucidating
the natural course and prognosis of IPF in different
populations, and can lead to a better understanding of
the disease etiology. However, if epidemiological data are
collected, it should include a broad systematic screening
of registries in the health care system, and a specific
reevaluation of the patient records, especially the evalua-
tions of pulmonary pathologists and radiologists. Novel
electronic databases will hopefully offer more compar-
able data in this setting in the near future.
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